Bonesupport Holding (OM:BONEX) Stock Looks Reasonable Even With Strong Cash Flow Value

Bonesupport Holding has delivered a very strong long term share price performance, which puts a lot of weight on what its future cash flows can support. With the stock recently changing hands at around SEK 254, the question is how much of that move is grounded in the cash the business can realistically generate over time.

• Over the past 5 years the stock has produced a very large gain, which raises the stakes on whether the current price still lines up with the cash flows investors expect to see.

• The company's business model in bone graft substitutes relies on turning clinical adoption into durable revenue and cash generation, so expectations for how efficiently sales convert into cash may be doing much of the work in today's valuation.

• What if you looked at Bonesupport Holding through its earnings instead? See why Bonesupport Holding's 77.8x P/E tells a different valuation story .

For investors, the debate is whether Bonesupport Holding's current share price is adequately explained by the cash flows implied by a Discounted Cash Flow (DCF) view over the coming years.

If you are weighing whether Bonesupport Holding's 5 year share price surge is fairly backed by its cash flows, it can help to compare it with other firms using a 188 high quality undervalued stocks .

Is Bonesupport Holding a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) approach here takes Bonesupport Holding's expected future cash generation and brings it back to today's money. Latest twelve month free cash flow sits at about SEK259.0 million, so the model already starts from a positive cash base before layering on growth assumptions.

The projections behind this DCF point to increasing free cash flow in SEK over the coming decade, followed by a slower second stage as the business matures. When those estimated streams are discounted back and compared with the current share price of SEK254.00, the DCF output indicates that the intrinsic value is substantially above where the stock trades today. That gap depends heavily on whether Bonesupport Holding can translate its bone graft adoption into the level of cash generation implied in the forecast set. Find out what Bonesupport Holding could be worth using our Discounted Cash Flow (DCF) estimate .

The Bonesupport Holding Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Bonesupport Holding pick up where the DCF puzzle leaves off. They spell out which future path for growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price, and turn a single valuation output into a set of concrete assumptions you can follow over time on the Community page to see whether they still match how the business is actually progressing.